Dr. Reddy's Laboratories Limited (BOM:500124)
India · Delayed Price · Currency is INR | Market Cap | 1.06T +4.0% |
| Revenue (ttm) | 345.83B +11.1% |
| Net Income | 56.59B +5.4% |
| EPS | 67.93 +5.6% |
| Shares Out | 832.57M |
| PE Ratio | 18.76 |
| Forward PE | 21.14 |
| Dividend | 8.00 (0.63%) |
| Ex-Dividend Date | Jul 10, 2025 |
| Volume | 36,527 |
| Average Volume | 140,628 |
| Open | 1,266.45 |
| Previous Close | 1,270.30 |
| Day's Range | 1,261.30 - 1,277.00 |
| 52-Week Range | 1,025.90 - 1,377.95 |
| Beta | 0.29 |
| RSI | 58.19 |
| Earnings Date | Jan 21, 2026 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i... [Read more]
Financial Performance
In fiscal year 2025, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.
Financial StatementsNews
Top losers among Nifty 50 stocks in midday trades today, Feb 10: Shriram Finance, Bajaj Finance, Dr. Reddy’s, SBI Life and more
Indian equity benchmarks were trading modestly higher in midday deals on February 10, with the NIFTY up 0.35% at 25,958.85...
India-US trade deal clarity: Pharma exporters gain edge in US; sector eyes growth boost
Indian drugmakers anticipate significant benefits from the proposed India-US trade agreement, offering much-needed clarity and stability for the lucrative US pharmaceutical market. This development is...
Pharma stocks surge: Aurobindo Pharma jumps 5%, Dr Reddy’s and Divi’s Labs rise over 3%
Pharma stocks traded broadly higher in early deals on February 3, tracking strong momentum across the sector. As of 9:32...
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's
Coya Therapeutics (COYA) raises $11.1M in a $4.40 private placement, backed by Dr. Reddy’s and Greenlight.
Dr. Reddy's (RDY) Invests in Coya Therapeutics' Private Placement
Dr. Reddy's (RDY) Invests in Coya Therapeutics' Private Placement
Pharma sector stocks down today, jan 29: Dr. Reddy’s Lab drops 2.45%, Zydus falls 1.44%, Aarti Drugs down 1.86%
The Indian pharma sector showed mixed to negative performance on January 29, 2026, as of 10:18 AM IST, amid broader...
Dr Reddy's Laboratories Ltd (RDY) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst ...
Dr Reddy's Laboratories Ltd (RDY) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst Challenges
Q3 2026 Dr Reddy's Laboratories Ltd Earnings Call Transcript
Q3 2026 Dr Reddy's Laboratories Ltd Earnings Call Transcript
Nifty 50 top gainers today, January 23: Dr. Reddy’s Laboratories, ONGC, Tech Mahindra, Hindalco Industries and more
Indian equity benchmarks closed lower on January 23 (IST), with selling pressure dragging the Nifty below 25,100 despite selective buying...
Stock market today: Top gainers and losers on Nifty50 and Sensex; check list
Indian stock markets opened flat on Friday, with both Nifty50 and Sensex eventually slipping into the red by afternoon trade. Foreign investors continued their selling spree, while domestic institutio...
Top gainers among Nifty 50 stocks in midday trades today, Jan 23: Asian Paints, Dr. Reddy’s Laboratorie, Hindustan Unilever and more
Indian equity benchmarks were trading lower in midday trade on January 23, with selling pressure seen across broader indices. Despite...
Pharma sector stocks today, Jan 23: Dr. Reddy’s Lab jumps 2.14%, Gland Pharma falls 1.71%, Torrent Pharma down 0.80%
The Indian pharma sector stocks showed mixed performance as of 10:20 AM IST on January 23, 2026. The broader market...
Top gainers among Nifty 50 stocks in midday trades today: Dr. Reddy’s Laboratories, Adani Enterprises, Bharat Electronics and more
Indian equity benchmarks were trading modestly higher in midday deals today. As of 12:25 PM, the Nifty 50 was up...
Dr. Reddy's (RDY) Reports Q3 Earnings with Revenue Growth
Dr. Reddy's (RDY) Reports Q3 Earnings with Revenue Growth
Dr. Reddy's GAAP EPS of ₹14.52, revenue of ₹87.27B
Pharma sector stocks rally today: Dr. Reddy’s Laboratories up 5%, Granules India jumps 4.33%, Strides Pharma jumps 4%
Indian pharmaceutical stocks showed gains in morning trade on January 22, 2026, amid a broader market uptrend. The BSE Sensex...
Top stocks for trade today, Jan 22: Eternal, Dr Reddy’s, Shriram Finance, Bank of India, Nestlé India and more
Indian equity markets are expected to witness stock-specific movements on Thursday, January 22, as investors react to a busy mix...
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
Dr. Reddy's (RDY) Gains Approval for Generic Ozempic in India
Dr. Reddy's (RDY) Gains Approval for Generic Ozempic in India
Dr. Reddy's wins India nod for generic Ozempic
Novo Nordisk (NVO) stock is in focus as Dr. Reddy’s (RDY) gets India approval for generic Ozempic, ahead of a planned launch in March. Read more here.
Dr Reddy’s to Start Selling Generic Ozempic in India From March
Indian drugmaker Dr Reddy’s Laboratories Ltd. is planning to launch a generic version of Novo Nordisk A/S’s Ozempic in March after the drug’s patent expiry, becoming one of the first firms to capture ...
Dr. Reddy’s Laboratories Q3 Results: Revenue up 4% YoY to Rs 8,726.8 crore, Profit rises to Rs 1,210 crore
Dr. Reddy’s Laboratories reported a steady set of earnings for the third quarter of FY26, with profit after tax attributable...
Top Q3 results today, January 21: Eternal, Dr Reddy’s Laboratories, Bank of India, Waaree Energies, PNB Housing Finance and more to announce earnings
Several listed companies are scheduled to announce their financial results for the quarter ended December 2025 (Q3 FY26) on Wednesday,...
Dr. Reddy's Q3 Earnings Preview
Cyber Fraud Targeting Drugmaker Dr Reddy's Busted, Rs 2.16 Crore Recovered
Group Pharmaceuticals was due to receive a payment of Rs 2.16 crore from Dr. Reddy's Laboratories. However, hackers gained access to their emails and diverted funds.